Get started
Author

Brian Andrew Jonas

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
2020 · Courtney D. DiNardo, Brian A. Jonas, et al. · New England Journal of Medicine · 2,886
PDF
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
2018 · Courtney D. DiNardo, Keith Pratz, et al. · Blood · 1,823
PDF
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
2018 · Courtney D DiNardo, Keith W Pratz, et al. · The Lancet Oncology · 722
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
2019 · Jorge E Cortes, Samer Khaled, et al. · The Lancet Oncology · 487
Long‐term follow‐up of VIALE‐A : Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia
2024 · Keith W. Pratz, Brian A. Jonas, et al. · American Journal of Hematology · 237
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
2023 · Daniel A. Pollyea, Jessica K. Altman, et al. · Journal of the National Comprehensive Cancer Network · 199
PDF
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
2019 · Brian A. Jonas, Daniel A. Pollyea · Leukemia · 183
PDF
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
2021 · Keith W. Pratz, Brian A. Jonas, et al. · Journal of Clinical Oncology · 180
PDF
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study
2020 · Daniel A. Pollyea, Keith Pratz, et al. · American Journal of Hematology · 166
PDF
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
2024 · Hartmut Döhner, Keith W. Pratz, et al. · Blood · 156
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
2022 · Daniel A. Pollyea, Keith W. Pratz, et al. · Clinical Cancer Research · 155
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
2023 · Stéphane de Botton, Pierre Fenaux, et al. · Blood Advances · 136
PDF
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022
2022 · Peter L. Greenberg, Richard M. Stone, et al. · Journal of the National Comprehensive Cancer Network · 127
PDF
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
2022 · Justin M Watts, Maria R Baer, et al. · The Lancet Haematology · 122
Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia
2019 · Bruno C. Medeiros, Steven M. Chan, et al. · American Journal of Hematology · 102
PDF
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia
2021 · Daniel J. DeAngelo, Brian A. Jonas, et al. · Blood · 98
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
2022 · Naval G. Daver, Monique Dail, et al. · Blood · 97
PDF
SMRT and N-CoR Corepressors Are Regulated by Distinct Kinase Signaling Pathways
2004 · Brian A. Jonas, Martin L. Privalsky · Journal of Biological Chemistry · 85
PDF
ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine
2022 · Hartmut Döhner, Keith W. Pratz, et al. · Blood · 84
A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia
2021 · Gautam Borthakur, Olatoyosi Odenike, et al. · Cancer · 71
Corepressors: Custom Tailoring and Alterations While you Wait
2005 · Michael Goodson, Brian A. Jonas, et al. · Nuclear Receptor Signaling · 70
PDF
Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
2024 · Bijal Shah, Ryan J. Mattison, et al. · Journal of the National Comprehensive Cancer Network · 68
Alternative mRNA Splicing of SMRT Creates Functional Diversity by Generating Corepressor Isoforms with Different Affinities for Different Nuclear Receptors
2005 · Michael L. Goodson, Brian A. Jonas, et al. · Journal of Biological Chemistry · 65
A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy
2015 · Courtney DiNardo, Daniel Pollyea, et al. · Blood · 62
Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia
2017 · Gwendolyn Ho, Brian A. Jonas, et al. · British Journal of Haematology · 60
Works count: 288
Citation count: 10,360
H-index: 36
I10-index: 96
Year
Topic
Type